A Behavioral Trial for the Treatment of Methamphetamine Dependence. - 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00033124
Recruitment Status : Unknown
Verified August 2003 by National Institute on Drug Abuse (NIDA).
Recruitment status was:  Active, not recruiting
First Posted : April 8, 2002
Last Update Posted : January 11, 2017
Information provided by:
National Institute on Drug Abuse (NIDA)

Brief Summary:
The purpose of this study is to examine behavioral treatment for methamphetamine dependence.

Condition or disease Intervention/treatment Phase
Substance-Related Disorders Behavioral: Behavior Therapy Phase 2

Detailed Description:
To characterize meth. withdrawal symptoms using a multidimensional withdrawal questionnaire; to field test and investigate the effect of using an algorithm developed for discriminating between new use and residual carry-over of meth metabolites in urine and to evaluate the treatment response of meth. users to participation in the thrice weekly psychosocial protocol to be used as a "platform" in future pharmacotherapy trials.

Study Type : Interventional  (Clinical Trial)
Enrollment : 50 participants
Primary Purpose: Treatment
Official Title: Behavioral Trial for the Treatment of Methamphetamine Dependence
Study Start Date : July 2001
Study Completion Date : June 2002

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. Withdrawal symptoms
  2. New Use algorithm

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 99 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Male or Female at least 18 yrs of age; DSM-4 diagnosis of methamphetamine (METH) dependence; be willing to comply with study procedures; verbalize understanding of consent and provide written consent and willingness to complete study procedures; be seeking treatment for METH dependence.

Exclusion Criteria:

Additional criteria available during screening at the site.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00033124

United States, California
South Bay Treatment Center
Chula Vista, California, United States, 91911
Matrix Institute on Addictions
Costa Mesa, California, United States, 92627
United States, Hawaii
John A. Burns School of Medicine
Honolulu, Hawaii, United States, 96813
United States, Iowa
Powell Chemical Dependency Center
Des Moines, Iowa, United States, 50316
United States, Missouri
Comprehensive Mental Health Services, Inc
Independence, Missouri, United States, 64052
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Principal Investigator: Richard Rawson, Ph.D. National Institute on Drug Abuse (NIDA) Identifier: NCT00033124     History of Changes
Obsolete Identifiers: NCT00024739
Other Study ID Numbers: NIDA-CTO-0009-1
First Posted: April 8, 2002    Key Record Dates
Last Update Posted: January 11, 2017
Last Verified: August 2003

Additional relevant MeSH terms:
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Central Nervous System Stimulants
Physiological Effects of Drugs
Autonomic Agents
Peripheral Nervous System Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Dopamine Uptake Inhibitors